Gilead Builds Japan Oncology Presence With Trodelvy
Yescarta Also Back In House
Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.
![Gilead aims to launch Trodelvy in Japan in 2024, where its Phase III for TNBC and lung cancer has been ongoing .](https://insights.citeline.com/resizer/v2/S6Q3UI2KERLOLBBSEJ6ECIV5VM.jpg?smart=true&auth=830acef19a0e849e6084da5279c3be8109580543bea9ea17f62db7dd4dde0be7&width=700&height=394)